Atherosclerosis Drugs Market
Atherosclerosis Drugs Market By Drug Class (Anti-platelet Medications, Cholesterol Lowering Medications, Beta Blockers, Diuretics, Calcium Channel Blockers), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region - Global Forecast 2020 to 2027
Atherosclerosis Drugs Market: Nanotechnology to Upgrade Quality of Drugs
Competency of nano polymers in imaging further broadens the scope of nanotechnology in the diagnosis of cardiovascular disorders, which makes it the present and the future technology of atherosclerosis drugs.
Nanotechnology is adding a new paradigm in the development of atherosclerosis drugs, owing to its selective drug delivery system that only targets damaged tissues. One such nano polymer, E-selectin-targeting polymer, is used for imaging and drug delivery applications to improve the function of heart muscles.
Though technological advancements and demand for drugs are growing at a notable rate, a large number of individuals remain undiagnosed. Low diagnostic rates could hamper the growth potential of the atherosclerosis drugs market during the forecast period (2020-2027).
Retail Pharmacies Gaining Prominence in Atherosclerosis Drugs Market
Hospital pharmacies boast of well-stocked inventory with a wide range of prescribed and OTC medications, which makes it convenient for individuals to makes purchases immediately after diagnosis. Numerous government-held hospital pharmacies offer medications at low rates, which further becomes a viable sales opportunity.
Hospital pharmacies are projected to account for around 46% share in the atherosclerosis drugs market by 2027. However, they could lose market share to retail pharmacies, to some extent, on the back of a large chain of retail pharmacies at key locations, which makes it easy for individuals to refill their drug supplies.
Besides this, in recent times, retail pharmacists are also playing a consultative role, which is likely to influence reliance on retail pharmacies. On account of growing popularity, retail pharmacies are set to register a value equal to US$ 24 Bn by 2027.
Avail customized purchase options for your needs
Growing Popularity of Generic Drugs – A Concern for North America, an Opportunity for Asia Pacific
Powerful forces at play attributing a high share to the North American atherosclerosis drugs market majorly include large public funding. The American Heart Association actively supports the research & development endeavours of market players, intended towards improving the cardiovascular health of the U.S. population.
Besides this, initiatives taken by the government to upgrade healthcare infrastructure and increase awareness regarding the treatment of numerous disorders are likely to augment diagnostic and drug adoption rates. On the back of numerous favourable drivers, the North America atherosclerosis drugs market is projected to account for 34% market share by 2027.
Though North America holds a leading position in the global atherosclerosis drugs market, increasing sales of generic drugs are impeding the revenue potential of leading players operating in this region. However, the Asia Pacific atherosclerosis drugs market is thriving on the back of growing sales of generic drugs, as a large number of prominent and emerging players are working towards their development.
In addition, Asia Pacific is a price-sensitive region, wherein, affordability of individuals plays a pivotal role in their purchase decisions. Growing preference for generic drugs over branded ones, in parallel with rising awareness regarding atherosclerosis disorders, would create a conducive environment for market growth during the forecast period.
An Adaptive Approach to Modern-day Research Needs
Atherosclerosis Drugs Market – Assessment of Key Segments
Authors of this comprehensive study have classified the atherosclerosis drugs market into key segments for an in-depth study of the market. Categorisation of the atherosclerosis drugs market is based on drug class, distribution channel, and region. This detailed study also offers information about the incremental opportunity present in the atherosclerosis drugs market during the forecast period. Key segments considered while studying the atherosclerosis drugs market include:
- FAQs -
Need an Exclusive Report for your Unique Requirement?
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.